CAMPBELL, CA -- (Marketwired) -- 09/06/17 -- VIVUS, Inc. (NASDAQ: VVUS) (the "Company"), a biopharmaceutical company committed to the development and commercialization of innovative therapies focusing on treatments for patients with serious unmet medical needs, today announced that the European
CAMPBELL, CA , and SAN GWANN, MALTA -- (Marketwired) -- 09/05/17 -- VIVUS, Inc. (NASDAQ: VVUS) and Alvogen Malta Operations (ROW) Ltd , today announced an agreement under which Alvogen will market Qsymia ® (phentermine and topiramate extended-release) in the Republic of Korea for the treatment of
CAMPBELL, CA -- (Marketwired) -- 08/30/17 -- VIVUS, Inc. (NASDAQ: VVUS) announced today that it has entered into a settlement agreement with Dr. Reddy's Laboratories, S.A. and Dr. Reddy's Laboratories, Inc. (Dr. Reddy's) resolving patent litigation related to Qsymia® (phentermine and topiramate
CAMPBELL, CA -- (Marketwired) -- 07/05/17 -- VIVUS, Inc. (NASDAQ: VVUS) announced today that it has entered into a settlement agreement with Actavis Laboratories FL (Actavis) resolving patent litigation related to Qsymia® (phentermine and topiramate extended-release) capsules CIV.
CAMPBELL, CA , and SAN CARLOS, CA -- (Marketwired) -- 01/09/17 -- VIVUS, Inc. ( NASDAQ : VVUS) and Selten Pharma, Inc. , announced VIVUS' acquisition from Selten of exclusive, worldwide rights for the development and commercialization of tacrolimus and ascomycin for the treatment of Pulmonary
